UK watchdog says Cochlear's Oticon Medical deal could harm market

  • 📰 Reuters
  • ⏱ Reading Time:
  • 28 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 97%

مصر أخبار أخبار

مصر أحدث الأخبار,مصر عناوين

Britain's Competition and Markets Authority said on Thursday that Australian hearing device maker Cochlear's purchase of Demant's hearing implants business could hurt competition and mean higher prices for the National Health Service.

Demant said that irrespective of the outcome of ongoing investigations by competition authorities, it remained committed to its decision to "discontinue" its Oticon Medical as it had already concluded it had no prospect of becoming a global leader in hearing implants within a reasonable timeframe.

The deal is also under investigation by the European Union and Australian antitrust regulators, and is pending clearance under French Foreign Direct Investment rules. The CMA has set a June 5 deadline for its in-depth probe of the deal, which Cochlear said was no longer expected to close before June 30.

The regulator said the combined entity would leave only a single supplier of passive bone conductive solution products in Britain and would dominate the supply of BCS products in the country, with a share well above 90%.

لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 2. in EG
 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.

مصر أحدث الأخبار, مصر عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Alabama Medical Cannabis Commission deems 90 applicants for medical cannabis business licenseSelect businesses in Alabama are now one step closer to potentially receiving a medical cannabis business license.
مصدر: FOX10News - 🏆 581. / 51 اقرأ أكثر »